Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Novel computational framework developed for real-time, personalized heart rate variability monitoring

Real-time and early detection of minute changes in the functioning of the cardiovascular system is crucial for managing critically ill patients, such as newborns and older adults, and can significantly affect their outcomes.

10 Feb 2026

SPT Labtech and Bellbrook Labs introduce high-throughput screening platform for cancer research

SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life sciences, and BellBrook Labs, a pioneer in high-throughput screening (HTS) assay tools, today announced a collaboration to advance cancer research.

9 Feb 2026

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays

Synthace, the leader in software and services for assay development, today announced a collaboration with Charles River Laboratories International, Inc. (Charles River), a leading global drug discovery, development, testing, and manufacturing solutions provider.

9 Feb 2026

AI model accelerates antibody production and clone selection

As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions.

9 Feb 2026

Chronic brain compression triggers neuron death through multiple pathways

To think, feel, talk and move, neurons send messages through electrical signals in the brain and spinal cord.

9 Feb 2026

Sustainable pharmacy initiatives needed to reduce environmental harm from medicines

The group of the EHU - University of the Basque Country is proposing various initiatives designed to reduce the presence of medicines in the environment and, consequently, their effects on human health.

6 Feb 2026

New DNA-based vaccine scaffolds boost targeted immune responses to HIV

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein scaffolding that mimics a virus.

6 Feb 2026

Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026

Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows.

5 Feb 2026

Study identifies genetic fingerprint of neuropathic pain neurons

Researchers from The University of Texas at Dallas and their international colleagues have determined the molecular signature of human sleeping - or silent - nociceptors: sensory neurons that are unresponsive to touch or pressure yet are key culprits in neuropathic pain.

4 Feb 2026

Advancing brain microphysiological systems for in vitro neurotoxicity and cognitive function testing

Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling.

From Yokogawa Life Science 3 Feb 2026

Engineering-driven startups at ASU advance biomedical innovation

The future of engineering-driven health innovation is currently unfolding at Arizona State University.

31 Jan 2026

Evosep launches IQ/OQ protocols for the Evosep Eno System at WCBP 2026

Evosep is proud to announce a major advancement in quality assurance for pharmaceutical and regulated laboratories with the introduction of Installation Qualification (IQ) and Operational Qualification (OQ) protocols for its Evosep Eno system.

From Evosep 30 Jan 2026

CDD European Life Science Community Meeting

Collaborative Drug Discovery's Community Meeting brings the European technology and scientific communities together.

From Collaborative Drug Discovery, Inc. 30 Jan 2026

Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

29 Jan 2026

Brain protein CUL5 protects neurons by clearing toxic tau clumps

Researchers at UC San Francisco have identified a hazardous waste collector in the brain that disposes of the toxic clumps of tau protein that can lead to dementia.

28 Jan 2026

Exploring Targeted Protein Degradation as a New Strategy to Tackle Antimicrobial Resistance

Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria.

28 Jan 2026

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

iXCells Biotechnologies ("iXCells"), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud Biosciences, an innovator in organoid development and complex 3D biology, today announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.

27 Jan 2026

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

27 Jan 2026

Selective inhibition of cPLA2 shows promise against Alzheimer's-related brain inflammation

A multidisciplinary USC research team has identified new compounds that may target a key driver of brain inflammation linked to Alzheimer's disease. Their research just published in the Nature publication npj Drug Discovery.

24 Jan 2026

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 inhibitor targeting inflammation and neurodegenerative disorders, has recently received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA), intended for the treatment of Parkinson's Disease.

23 Jan 2026

Drug Discovery News and Research

Further Reading

Novel computational framework developed for real-time, personalized heart rate variability monitoring

SPT Labtech and Bellbrook Labs introduce high-throughput screening platform for cancer research

Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays

AI model accelerates antibody production and clone selection

Chronic brain compression triggers neuron death through multiple pathways

Sustainable pharmacy initiatives needed to reduce environmental harm from medicines

New DNA-based vaccine scaffolds boost targeted immune responses to HIV

Revvity unveils new high-impact discovery platforms and showcases recent innovations at SLAS2026

Study identifies genetic fingerprint of neuropathic pain neurons

Advancing brain microphysiological systems for in vitro neurotoxicity and cognitive function testing

Engineering-driven startups at ASU advance biomedical innovation

Evosep launches IQ/OQ protocols for the Evosep Eno System at WCBP 2026

CDD European Life Science Community Meeting

Study offers a practical strategy to enhance effectiveness of immune checkpoint inhibitors

Brain protein CUL5 protects neurons by clearing toxic tau clumps

Exploring Targeted Protein Degradation as a New Strategy to Tackle Antimicrobial Resistance

iXCells Biotechnologies and Rosebud Biosciences partner to advance organoid-based models for rare diseases

Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs

Selective inhibition of cPLA2 shows promise against Alzheimer's-related brain inflammation

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery